Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.
Kidney Neoplasms
DRUG: SU-011,248
The primary endpoint was overall response rate (ORR) and the ORR achieved for the study was 40%.
The secondary endpoints included time to progression (TTP) and overall survival (OS). The median TTP for the study was 8.7 months and the median OS was 16.4 months. SU011248 was generally well tolerated.
The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.